

**Evidence Tables:**

**NUTRI 2: In patients with acute alcohol-related pancreatitis, what is the safety and efficacy of:**

- a) nutritional supplementation vs. no supplementation
- b) early (first 48hrs) vs. late supplementation
- c) enteral vs. parenteral nutrition
- d) NJ vs. NG

**1. Enteral vs. parenteral (+ parenteral vs. none/enteral vs. none)**

Reference	Study type/ Evidence level	Number of patients	Patient characteristics	Intervention	Comparison	Length of follow-up	Outcome measures	Source of funding
<b>Petrov MS, Pylypchuk RD, Emelyanov NV. Systematic review: Nutritional support in acute pancreatitis. <i>Alimentary Pharmacology and Therapeutics</i>. 2008; 28(6):704-712.</b>	1+ SR  Jadad scale used to assess quality of studies  None of the included studies were double-blinded. Drop outs seen in 6/15 studies (range 1-4 drop outs). Method of treatment assignment was not reported in 7/15 studies.	N=15 studies  N= 617 patients  N= 266 in enteral nutrition group  N= 280 in the parenteral nutrition group  N=71 with no supplementary nutrition	N=9 studies included patients with severe acute pancreatitis. N=6 studies included patients with mild and severe acute pancreatitis. N=11 studies compared enteral vs. parenteral nutrition N=3 studies compared parenteral nutrition vs. no supplementary nutrition. N=1 study compared enteral nutrition vs. no supplementary nutrition.	1) enteral nutrition 2) parenteral nutrition 3) enteral nutrition	1) parenteral nutrition 2) no supplementary nutrition 3) no supplementary nutrition	Not reported	Total infectious complications, in-hospital mortality.	None reported

Reference	Study type/ Evidence level	Number of patients	Patient characteristics	Intervention	Comparison	Length of follow- up	Outcome measures	Source of funding
<p><b>Effect Size</b></p> <p>Outcomes</p> <p><b>1. Enteral nutrition vs. parenteral nutrition (11 RCTS, n=453 patients)</b></p> <ul style="list-style-type: none"> <li>• Infectious complications           <ul style="list-style-type: none"> <li>- Enteral nutrition resulted in a significantly significant 59% reduction</li> <li>- Enteral group 33/204; parenteral group 89/226</li> <li>- Risk ratio 0.41 (95% CI 0.30, 0.57) P&lt;0.00001</li> </ul> </li> <li>• In-hospital mortality           <ul style="list-style-type: none"> <li>- Enteral nutrition resulted in a non-significant 40% reduction</li> <li>- Enteral group 16/191; parenteral group 34/213</li> <li>- Risk ratio 0.60 (95% CI 0.32, 1.14) p=0.12</li> </ul> </li> </ul> <p>N.B. Heterogeneity explained by random variation.</p> <p><b>2. Parenteral nutrition vs. supplementary nutrition (3 RCTs, n=113 patients)</b></p> <ul style="list-style-type: none"> <li>• Infectious complications           <ul style="list-style-type: none"> <li>- Parenteral nutrition resulted in a statistically non-significant increase of 36% in the risk of infectious complications</li> <li>- Parenteral group 8/49; no nutrition group 8/49</li> <li>- Risk ratio 1.36 (95% CI 0.18-10.40) p=0.77 (moderate heterogeneity between study results)</li> </ul> </li> <li>• In-hospital mortality           <ul style="list-style-type: none"> <li>- Parenteral nutrition resulted in a statistically significant 64% reduction</li> <li>- Parenteral group 4/56; no nutrition group 13/57</li> <li>- Risk ratio 0.36 (95% CI 0.13, 0.97) p=0.04 (no heterogeneity)</li> </ul> </li> </ul> <p><b>3. Enteral nutrition vs. no supplementary nutrition (1 RCT, n=27 patients)</b></p> <ul style="list-style-type: none"> <li>• As there was not enough data for direct meta-analysis, indirect adjusted meta-analysis was applied (validated by a number of authors and applied in a number of clinical settings).</li> <li>• Infectious complications           <ul style="list-style-type: none"> <li>- Risk reduced non-significantly by 44% with the use of enteral nutrition over no nutrition</li> <li>- Ratio of RRs (95% CI): 0.56 (0.07-4.32) p=0.58</li> <li>- This difference was probably non-significant due to the small sample size.</li> </ul> </li> <li>• In-hospital mortality           <ul style="list-style-type: none"> <li>- Enteral nutrition resulted in a 78% reduction in risk</li> </ul> </li> </ul>								

DRAFT FOR CONSULTATION

Reference	Study type/ Evidence level	Number of patients	Patient characteristics	Intervention	Comparison	Length of follow-up	Outcome measures	Source of funding															
<p>- Ratio of RRs (95% CI): 0.22 (0.07-0.70) p= 0.01</p> <ul style="list-style-type: none"> <li>• Limitations of indirect adjusted meta-analysis:           <ul style="list-style-type: none"> <li>- The findings may not completely correspond to the results of a meta-analysis of direct head-to-head randomized comparisons.</li> </ul> </li> </ul> <p><b>Limitations:</b></p> <ul style="list-style-type: none"> <li>- No mention of aetiology of pancreatitis- unclear number alcohol related.</li> </ul>																							
<p><b>McClave SA, Greene LM, Snider HL et al.</b>  <b>Comparison of the safety of early enteral vs parenteral nutrition in mild acute pancreatitis.</b>  <i>Journal of Parenteral &amp; Enteral Nutrition.</i>            1997;            21(1):14-20.</p>	<p>1+ RCT</p> <p>Randomised, blinding and allocation concealment unclear</p> <p>Underpowered</p>	N=32	<p><b>Inclusion criteria:</b> patients with acute pancreatitis or an acute flare of chronic pancreatitis, characterized by abdominal pain with elevated amylase and lipase.</p> <p><b>Exclusion criteria:</b> patients with evidence of short bowel syndrome, Crohn's disease, major pancreatic resection, or failure to start total enteral nutrition (TEN) or total parenteral nutrition (TPN) within 48hrs of admission. Patients were excluded if they failed to adhere to dietary restrictions or to the protocol terms for enteral tube placement.</p> <p><b>Patient Characteristics:</b> no significant differences between the 2 groups with respect to age, sex, aetiology, initial Ranson criteria, APACHE III, or MOF scores.</p> <table border="1"> <thead> <tr> <th></th> <th>TEN</th> <th>TPN</th> </tr> </thead> <tbody> <tr> <td>Age (yrs)</td> <td>47.6±4.0</td> <td>45.1±4.2</td> </tr> <tr> <td>% Male</td> <td>68.7±12.0</td> <td>81.2±10.1</td> </tr> <tr> <td>% alcohol related</td> <td>75.0±11.2</td> <td>62.5±12.5</td> </tr> <tr> <td>Initial Ranson</td> <td>1.3±0.35 (43.7%)</td> <td>1.3±0.35 (27.5%)</td> </tr> </tbody> </table>		TEN	TPN	Age (yrs)	47.6±4.0	45.1±4.2	% Male	68.7±12.0	81.2±10.1	% alcohol related	75.0±11.2	62.5±12.5	Initial Ranson	1.3±0.35 (43.7%)	1.3±0.35 (27.5%)	<p>TPN –infused through a central or peripheral line</p> <p>Both groups were placed on isocaloric-isonitrogenous feedings.</p> <p>N=16</p>	<p>TEN – Peptamen infused through NJ tube</p> <p>N=16</p>	<p>Until discharge (not specified)</p>	<p>Safety parameters, Ranson criteria, APACHE III criteria, MOF score, pain score, nosocomial infection, mortality, percent of goal calories achieved, days to advancement to diet by mouth, and length of hospitalization.</p>	<p>Clintec Nutrition Company</p>
	TEN	TPN																					
Age (yrs)	47.6±4.0	45.1±4.2																					
% Male	68.7±12.0	81.2±10.1																					
% alcohol related	75.0±11.2	62.5±12.5																					
Initial Ranson	1.3±0.35 (43.7%)	1.3±0.35 (27.5%)																					

DRAFT FOR CONSULTATION

Reference	Study type/ Evidence level	Number of patients	Patient characteristics	Intervention	Comparison	Length of follow-up	Outcome measures	Source of funding															
			<table border="1"> <tr> <td>criteria (%&gt;2)</td> <td></td> <td></td> </tr> <tr> <td>Initial APACHE III score</td> <td>17.5±4.1</td> <td>22.4±5.0</td> </tr> <tr> <td>Initial MOF score</td> <td>1.3±0.45</td> <td>1.1±0.49</td> </tr> </table>	criteria (%>2)			Initial APACHE III score	17.5±4.1	22.4±5.0	Initial MOF score	1.3±0.45	1.1±0.49											
criteria (%>2)																							
Initial APACHE III score	17.5±4.1	22.4±5.0																					
Initial MOF score	1.3±0.45	1.1±0.49																					
<p><b>Effect Size</b>  <b>Outcomes</b>  <b>1. Length of stay (days)</b></p> <ul style="list-style-type: none"> <li>TEN: 9.7± 1.3</li> <li>TPN: 11.9 ± 2.6</li> </ul>																							
Reference	Study type/ Evidence level	Number of patients	Patient characteristics	Intervention	Comparison	Length of follow-up	Outcome measures	Source of funding															
<b>Abou-Assi S, Craig K, O'Keefe SJ.</b> <b>Hypocaloric jejunal feeding is better than total parenteral nutrition in acute pancreatitis: results of a randomized comparative</b>	1+ RCT  Randomised, ITT  unclear allocation concealment and blinding	N=53	<p><b>Inclusion criteria:</b> patients with acute pancreatitis who were in need of nutritional support, with acute abdominal pain, 3-fold elevation of serum pancreatic enzymes, amylase, lipase.  <b>Exclusion criteria:</b> not reported  <b>Patient Characteristics:</b></p> <table border="1"> <thead> <tr> <th></th> <th>EN group</th> <th>TPN group</th> </tr> </thead> <tbody> <tr> <td>Age (yr)</td> <td>48 (3)</td> <td>50 (3)</td> </tr> <tr> <td>F/M</td> <td>10/16</td> <td>14/13</td> </tr> <tr> <td>Ethnicity (black/white/hispanic)</td> <td>14/11/1</td> <td>14/12/1</td> </tr> <tr> <td>Ranson's criteria</td> <td>3.1 (0.5)</td> <td>2.5 (0.4)</td> </tr> </tbody> </table>		EN group	TPN group	Age (yr)	48 (3)	50 (3)	F/M	10/16	14/13	Ethnicity (black/white/hispanic)	14/11/1	14/12/1	Ranson's criteria	3.1 (0.5)	2.5 (0.4)	TPN (via central line)  N=27	EN (via NJ tube)  N=26	3 days post weaning from nutritional support	Duration of hospitalization, duration of intervention, tolerance, cost-effectiveness	American College of gastroenterology and the Medical College of Virginia Hospitals
	EN group	TPN group																					
Age (yr)	48 (3)	50 (3)																					
F/M	10/16	14/13																					
Ethnicity (black/white/hispanic)	14/11/1	14/12/1																					
Ranson's criteria	3.1 (0.5)	2.5 (0.4)																					

DRAFT FOR CONSULTATION

Reference	Study type/ Evidence level	Number of patients	Patient characteristics	Intervention	Comparison	Length of follow-up	Outcome measures	Source of funding			
<b>study. <i>Am J Gastroenterol</i> . 2002; 97(9):2255-2262.</b>			<table border="1"> <tr> <td>Duration of nutrition (days)</td> <td>6.7 (1.1)*</td> <td>10.8 (1.7)</td> </tr> </table> <p>* p=0.03 62% alcohol related</p>	Duration of nutrition (days)	6.7 (1.1)*	10.8 (1.7)					
Duration of nutrition (days)	6.7 (1.1)*	10.8 (1.7)									

**Effect Size**

Outcomes

**1. Length of hospital stay (days)**

- EN group: 14.2 (1.9)
- TPN group: 18.4 (1.9)

Reference	Study type Evidence level	Number of patients	Patient characteristics	Intervention	Comparison	Length of follow-up	Outcome measures	Source of funding
<b>Eckerwall GE, Axelsson JB, Andersson RG. Early nasogastric feeding in predicted severe acute pancreatitis: A clinical, randomized study. <i>Annals of Surgery</i>. 2006; 244(6):959-965.</b>	RCT 1+ Randomisati on – balanced with the use of four blocks Concealment allocation – sealed number envelopes Blinding - none	N=50	<p>Patients with a clinical diagnosis of acute pancreatitis</p> <p>Inclusion criteria: abdominal pain, amylase 3 or more time the upper limit of normal, onset of abdominal pain within 48 hrs, APACHE II 8 or more and/or CRP of 150 mg/L or more and/or pancreatic liquid shown on CT</p> <p>Exclusion criteria: acute pancreatitis due to surgery, chronic pancreatitis exacerbation</p> <p>Patient population: parental Mean age 68, alcohol aetiology 4.26, APACHE II mean 9</p> <p>Enteral</p>	<p>Parental</p> <p>N=26</p> <p>Feeding through peripheral route except for 2 patients who received a central venous catheter</p> <p>Duration not specified</p>	<p>Enteral</p> <p>N=24</p> <p>Feeding through clinicfeeding tube (75%) and NG tube (25%)</p> <p>Duration not specified</p>	10 days	Multiple organ failure Length of stay	None

DRAFT FOR CONSULTATION

Reference	Study type/ Evidence level	Number of patients	Patient characteristics	Intervention	Comparison	Length of follow-up	Outcome measures	Source of funding
			<p>Mean age 71 yrs, alcohol aetiology 3.24, APACHE II mean 10</p> <p>Total Alcohol related:14%</p> <p>There were no differences at baseline</p>					
<p>Effect</p> <p>Parental vs enteral</p> <p>Length of stay</p> <p>Median 9 (7 to 14) vs 7 (6 to 14) days (p=0.19)</p> <p>Multiple organ failure</p> <p>1/26 vs 1/24</p>								
<p><b>Petrov MS, Kukosh MV, Emelyanov NV. A randomized controlled trial of enteral versus parenteral feeding in patients with predicted severe acute pancreatitis shows a significant reduction in mortality and in infected pancreatic complications</b></p>	<p>RCT 1+ Randomisation – no details Concealment allocation – computerised Power analysis ITT Blinding not specified</p>	<p>N=70</p> <p>Drop-outs N=1</p>	<p>Patients with severe acute pancreatitis within 72 hrs of onset.</p> <p>Diagnosis was based on clinical and biochemical presentation (upper abdominal pain and serum amylase at least three times the upper reference limit). Predicted severe acute pancreatitis was defined as: APACHE II of 8 or more and/or CRP level &gt; 150 mg/l</p> <p>Patient population: Enteral Mean age 51 yrs, male:female 27:8, APACHE II mean 12, alcohol aetiology 11/35</p> <p>Parental Mean age 52 yrs, male:female 24:10, APACHE II mean 12.5, alcohol aetiology 15/34</p>	<p>Parental</p> <p>N=34</p> <p>Minimum duration 7 days</p> <p>Feeding through central venous catheter</p> <p>Duration not reported</p>	<p>Enteral</p> <p>N=35</p> <p>Minimum duration 7 days</p> <p>Feeding through NJ tube</p> <p>Duration not reported</p>	<p>Discharge</p>	<p>Multiple organ failure</p>	<p>None reported</p>

DRAFT FOR CONSULTATION

Reference	Study type/ Evidence level	Number of patients	Patient characteristics	Intervention	Comparison	Length of follow-up	Outcome measures	Source of funding
with total enteral nutrition. <i>Digestive Surgery. 2006; 23(5-6):336-344</i>			There were no differences at baseline					
Effect Parental vs enteral Multiple organ failure 17/34 vs 7/35 (p=0.02)								
<b>Gupta R, Patel K, Calder PC et al. A randomised clinical trial to assess the effect of total enteral and total parenteral nutritional support on metabolic, inflammatory and oxidative markers in patients with predicted severe acute pancreatitis (APACHE II &gt; or =6). <i>Pancreatology.</i></b>	RCT 1+  Randomisation – no detail Concealment allocation – sealed envelopes Blinding not specified	N=17	<p>Patients with acute pancreatitis (defined as abdominal pain and serum amylase concentration of 1000 U/l or more). The diagnosis of predicted severe acute pancreatitis was established by the presence of acute physiology, age and chronic health evaluation score (APACHE II) of 6 or more</p> <p>Patient population: Enteral Mean age 65 yrs, male:female 4:4, APACHE II mean 8, alcohol aetiology 1/8</p> <p>Parental Mean age 57 yrs, male:female 3:6, APACHE II mean 10, alcohol aetiology 5/9</p> <p>There were no differences at baseline</p>	<p>Parental N=9</p> <p>Feeding through central intravenous line</p> <p>Feeding was started as soon as possible after the diagnosis</p>	<p>Enteral N=8</p> <p>Feeding through NJ tube</p> <p>Feeding was started within 6 hrs of the diagnosis of predicted severe acute pancreatitis being made</p>	Discharge	Length of stay Non-respiratory failure	Nutrition

DRAFT FOR CONSULTATION

Reference	Study type/ Evidence level	Number of patients	Patient characteristics	Intervention	Comparison	Length of follow-up	Outcome measures	Source of funding
<b>2003; 3(5):406-413.</b>								
Effect Parental vs enteral Length of stay 10 (7 to 26) vs 7 (4 to 14) (p=0.05) Non-respiratory failure 3 vs 0								
<b>Kalfarentzos F, Kehagias J, Mead N et al. Enteral nutrition is superior to parenteral nutrition in severe acute pancreatitis: results of a randomized prospective trial. <i>British Journal of Surgery.</i> 1997; 84(12):1665-1669.</b>	RCT 1+  Randomisation – no details Concealment allocation – numbered envelopes Blinding not specified	N=38	Patients with acute severe pancreatitis  Inclusion criteria: 3 or more criteria according to the Imrie classification or APACHE II score of 8 or more, C-reactive protein > 120 mg/l within 48 hrs of admission, and grade D or E by CT according to Balthazar criteria  Patient population: Enteral Mean age 63, male:female 8:10, alcohol aetiology 3/18, mean APACHE II score 12.7  Parental Mean age 67, male:female 7:13, alcohol aetiology 2/20, mean APACHE II score 11.8  There were no differences at baseline	Parental  N=20  All patients required intensive monitoring for more than 72 hrs. Fluid replacement, prophylactic antibiotic and NG tube inserted  Feeding through subclavian polyurethane catheter  Duration not reported	Enteral  N=18  Through nasoenteric feeding tube	Discharge	Length of stay ARDS	None reported
Effect Enteral vs parental Hospital stay 40 (25 to 93) vs 39 (22-73)								



DRAFT FOR CONSULTATION

Reference	Study type/ Evidence level	Number of patients	Patient characteristics	Intervention	Comparison	Length of follow-up	Outcome measures	Source of funding	
ARDS 2 vs 4									
<b>Olaah A, Pardavi G, Belaagyi T et al. Early nasojejunal feeding in acute pancreatitis is associated with a lower complication rate. <i>Nutrition</i>. 2002; 18(3):259-262.</b>	RCT 1+  Randomisation - no details Concealment allocation – by birth date No power analysis Blinding not specified	N=89	<p>Patients with acute pancreatitis admitted to the surgical ward</p> <p>Inclusion criteria: clinical symptoms and laboratory signs of pancreatitis (amylase &gt; 200 U/L)</p> <p>Patients were included if they were admitted within 24 to 72 hrs after the onset of symptoms</p> <p>Exclusion criteria: evidence of biliary tract disease, patients with acute exacerbations of chronic pancreatitis</p> <p>Patient population: parental Mean age 43.8 yrs, male:female 42:6, alcohol aetiology:other 39:9</p> <p>Enteral Mean age 47.2 yrs, male:female 33:8 alcohol aetiology:other 33:8</p> <p>No differences at baseline reported</p>	<p>Parental N=48</p> <p>Therapy was initiated within 24 hrs of admission</p> <p>Placement of NG tube, gut rest (no oral feeding), and parental nutrition</p> <p>Duration range 5 to 16 days</p>		<p>Enteral N=41</p> <p>NJ tube within 24 hrs of admission</p> <p>Duration 5 to 9 days</p>	Discharge	Multi organ failure	None reported
<p>Effect Parental vs enteral MOF 5/48 vs 2/41 (ns) Severe pancreatitis – MoF</p>									

DRAFT FOR CONSULTATION

Reference	Study type/ Evidence level	Number of patients	Patient characteristics	Intervention	Comparison	Length of follow-up	Outcome measures	Source of funding	
5/10 vs 2/7 (ns)									
<b>Windsor AC, Kanwar S, Li AG et al. Compared with parenteral nutrition, enteral feeding attenuates the acute phase response and improves disease severity in acute pancreatitis. Gut. 1998; 42(3):431-435.</b>	RCT 1+ No details of randomisation No details of Concealment allocation No power analysis Radiologist blind	N=34  No drop-outs reported	<p>Patients with acute pancreatitis with a serum amylase of &gt; 1000 IU</p> <p>Exclusion criteria: patients without clinical evidence of acute pancreatitis and presenting more than 48 hrs after admission</p> <p>Patients were stratified according to the Glasgow score: 3 or more points = severe disease and less than three points mild/moderate disease</p> <p>Patient population: Parental Mean age 63 yrs, female:male 11:7, severe disease 7/18, mild/moderate disease 11/18, APACHE II score 4.5, alcohol aetiology 2/18</p> <p>Enteral Mean age 63 yrs, female:male 9:7, severe disease 6/16, mild/moderate disease 10/16 APACHE II score 8, alcohol aetiology 2/16</p> <p>There were no significant differences at baseline</p>	<p>Parental nutrition</p> <p>N=18</p> <p>Severe disease: delivered through central venous catheter</p> <p>Mild/moderate: peripheral long line</p> <p>48 hrs enrolment, 7 day nutritional support</p>	<p>Enteral nutrition</p> <p>N=16</p> <p>Severe disease: delivered through radiologically placed NJ tube</p> <p>Mild/moderate: oral nutrition supplements</p> <p>48 hrs enrolment, 7 day nutritional support</p>	Discharge	SIRS MOF LoS	None reported	
<p>Effect Enteral vs parental MOF 0 vs 5  LoS</p>									

Reference	Study type/ Evidence level	Number of patients	Patient characteristics	Intervention	Comparison	Length of follow-up	Outcome measures	Source of funding
-----------	-------------------------------	--------------------	-------------------------	--------------	------------	---------------------	------------------	-------------------

Median 12.5 (9.5 to 14) vs 15 (11 to 28) days (ns)

**2. Nutritional support vs. no nutritional support**

<p><b>Eckerwall GE, Tingstedt BB, Bergenzaun PE et al. Immediate oral feeding in patients with mild acute pancreatitis is safe and may accelerate recovery--a randomized clinical study. <i>Clinical Nutrition</i>. 2007; 26(6):758-763.</b></p>	RCT 1+	N=60	<p><b>Inclusion criteria:</b> clinical signs of mild acute pancreatitis, pancreas amylase <math>\geq</math> 3 times above normal, onset of abdominal pain within 48h, acute physiological and chronic health evaluation score (APACHE) II &lt;8 and C-reactive protein (CRP) &lt;150mg/L. <b>Exclusion criteria:</b> if acute pancreatitis was caused by surgery, trauma or cancer and if inflammatory bowel disease, stoma, short bowel, pregnancy or chronic pancreatitis with exacerbation were present and if the age was below 18. <b>Patient characteristics:</b></p> <table border="1"> <thead> <tr> <th></th> <th>Fasting</th> <th>Oral feeding</th> <th>P value</th> </tr> </thead> <tbody> <tr> <td>Age (years)</td> <td>52 (38-60)</td> <td>56 (48-72)</td> <td>0.22</td> </tr> <tr> <td>Sex male:female</td> <td>14:16</td> <td>13:17</td> <td>1.00</td> </tr> <tr> <td><b>Aetiology</b></td> <td></td> <td></td> <td></td> </tr> <tr> <td>Biliary</td> <td>14</td> <td>18</td> <td>0.44</td> </tr> <tr> <td>Alcohol</td> <td>5</td> <td>3</td> <td>0.71</td> </tr> <tr> <td>ERCP</td> <td>2</td> <td>2</td> <td>1.00</td> </tr> <tr> <td>Other</td> <td>1</td> <td>2</td> <td>1.00</td> </tr> </tbody> </table>		Fasting	Oral feeding	P value	Age (years)	52 (38-60)	56 (48-72)	0.22	Sex male:female	14:16	13:17	1.00	<b>Aetiology</b>				Biliary	14	18	0.44	Alcohol	5	3	0.71	ERCP	2	2	1.00	Other	1	2	1.00	Randomised, allocation concealment, unable to blind	N=59 completed (1 drop out in oral feeding group)	<p><b>Fasting</b> (+ iv fluids) - oral fluids and diet reintroduced in a traditional step-wise manner as tolerated.</p> <p>N=30</p> <p>See table below for more details</p>	<p><b>Immediate oral feeding</b> (+ iv fluids when needed)</p> <p>N=30 (1 dropped out n=29 completed)</p> <p>See table below for more details</p>	3 months	Pancreas-specific amylase, systematic inflammatory response (markers CRP + leukocytes), feasibility (abdominal pain+ frequency of GI symptoms); length of hospital stay.	Swedish Nutrition Foundation, Swedish Research Council, Foundation for Gut and Intestinal Research
		Fasting		Oral feeding	P value																																					
	Age (years)	52 (38-60)		56 (48-72)	0.22																																					
	Sex male:female	14:16		13:17	1.00																																					
	<b>Aetiology</b>																																									
	Biliary	14		18	0.44																																					
	Alcohol	5		3	0.71																																					
	ERCP	2		2	1.00																																					
	Other	1		2	1.00																																					

			Idiopathic	8	5	0.5 3					
			APACHE II	5 (3-6)	6 (4-6)	0.4 5					

**Effect Size**

Outcomes

**1. Nutritional outcome (mean values)**

	Fasting (n=30)	Oral feeding (n=29)	P value
iv fluids (days)	4 (3-6)	2 (1-3)	<0.001
Fasting (days)	3 (2-3)	0 (0-1)	<0.001
Solid food, on day	5 (4-7)	3 (2-4)	<0.001

**2. Systematic inflammatory response (CRP, leukocytes)**

- CRP values:
  - Fasting group: 81 (45-139)mg/L
  - Oral feeding group: 61 (26-127)mg/L
- Leukocyte values
  - Fasting group: 7.7 (6.4-10.8) 10<sup>9</sup>/L
  - Oral feeding group: 6.6 (6.3-10.2) 10<sup>9</sup>/L
- NS difference between groups in either marker of SIR (no figures provided)

**3. Mortality**

- No mortality in either group

**4. Pancreatic complications**

- No complications such as necrosis, abscess or pseudocysts in either group

**5. Operative interventions**

- No significant difference was seen between groups concerning the number of interventions performed during hospital stay (cholecystectomy and endoscopic retrograde cholangio-pancreatography)
  - 7/30 vs. 6/29, p>0.30

**6. Length of hospital stay**

- Significantly shorter in the oral feeding group compared to the fasting group:
  - 4 vs. 6 days; p=0.047
- By follow-up after 3 months, no. of readmissions was not significantly different across groups:

DRAFT FOR CONSULTATION

- Fasting group: 3 (10%)
- Oral feeding group: 2 (7%)
- $p > 0.30$

**Authors' conclusion:** '...the present study in patients with mild acute pancreatitis shows that immediate oral feeding was feasible and safe and may accelerate recovery without adverse gastrointestinal events.'

**Limitations:**

- not blinded (not possible)
- small sample size

Reference	Study type/ Evidence level	Number of patients	Patient characteristics	Intervention	Comparison	Length of follow-up	Outcome measures	Source of funding																								
<b>Xian-li H, Qing-jiu M, Jian-guo L et al. Effect of total parenteral nutrition (TPN) with and without glutamine dipeptide supplementation on outcome in severe acute pancreatitis (SAP). <i>Clinical Nutrition Supplements</i>. 2004; 1(1):43-47.</b>	RCT 1+  Randomised, blinding and allocation concealment unclear	N=64	<p><b>Inclusion criteria:</b> patients with severe acute pancreatitis (SAP) diagnosed by clinical evaluations, clinical biochemistry and CT scanning of the pancreas, according to the universal standard for SAP diagnosis in China.</p> <p><b>Exclusion criteria:</b> patients with acute fulminant pancreatitis; patients admitted more than 3 days after the onset of symptoms and patients with renal or liver dysfunction.</p> <p><b>Patient characteristics:</b> There was no difference between the 3 groups with regards to age, sex, status of illness and pathology.</p> <table border="1"> <thead> <tr> <th></th> <th>Gp I</th> <th>Gp II</th> <th>Gp III</th> </tr> </thead> <tbody> <tr> <td>Age (yrs)</td> <td>39.6±5.2</td> <td>40.2±7.8</td> <td>39.4±8.6</td> </tr> <tr> <td>Sex (M/F)</td> <td>12/11</td> <td>11/10</td> <td>11/9</td> </tr> <tr> <td>Aetiology</td> <td></td> <td></td> <td></td> </tr> <tr> <td>Biliogenic</td> <td>20</td> <td>18</td> <td>19</td> </tr> <tr> <td>Pancreatitis-</td> <td>3</td> <td>2</td> <td>2</td> </tr> </tbody> </table>		Gp I	Gp II	Gp III	Age (yrs)	39.6±5.2	40.2±7.8	39.4±8.6	Sex (M/F)	12/11	11/10	11/9	Aetiology				Biliogenic	20	18	19	Pancreatitis-	3	2	2	<p><b>Gp I: traditional conservative therapy</b> (iv fluids, electrolyte replacement, starvation treatment, NG decompression, analgesics, pancreatic exocrine secretion suppression, prophylactic antibiotics and necessary infusion of albumin or fresh plasma)</p>	<p><b>Gp II: traditional conservative therapy + TPN</b> (iso-caloric + iso-nitrogenous) n=21</p> <p><b>Gp III: traditional conservative therapy + TPN + additional glutamine dipeptide-supplementation</b> n=20</p> <p>Both groups commenced TPN within 24-48h after the liquid resuscitation and</p>	At least 2 weeks	Serum albumin, body weight, mortality, complications (ARDS, MOF, stress ulcer), pancreatic infection, recovery time of blood amylase, recovery time of abdominal distension, length of stay (LOS)	Not reported
					Gp I	Gp II	Gp III																									
				Age (yrs)	39.6±5.2	40.2±7.8	39.4±8.6																									
				Sex (M/F)	12/11	11/10	11/9																									
				Aetiology																												
				Biliogenic	20	18	19																									
Pancreatitis-	3	2	2																													

			crapulence (alcohol-related)				n=23	continued for at least 2 weeks.														
<p><b>Effect Size</b>  <b>Outcomes</b>  <b>1. MOF</b></p> <ul style="list-style-type: none"> <li>Gp I (conservative treatment): 4/23</li> <li>Gp II (conservative treatment+TPN): 2/21</li> <li>Gp III (conservative treatment +TPN+ additional glutamine dipeptide-supplementation): 0/20</li> </ul> <p><b>2. LOS</b></p> <ul style="list-style-type: none"> <li>Gp I (conservative treatment): 39.1 ±10.60 days</li> <li>Gp II (conservative treatment+TPN): 28.6 ± 6.90 days (p&lt;0.05 vs. Gp I)</li> <li>Gp III (conservative treatment +TPN+ additional glutamine dipeptide-supplementation): 25.3 ± 7.60 days (p&lt;0.01 vs. Gp I)</li> </ul>																						
Reference	Study type/ Evidence level	Number of patients	Patient characteristics	Intervention	Comparison	Length of follow-up	Outcome measures	Source of funding														
<p><b>Sax HC, Warner BW, Talamini MA et al. Early total parenteral nutrition in acute pancreatitis: lack of beneficial effects. American Journal of Surgery. 1987; 153(1):117-124.</b></p>	<p>1+ RCT  Randomized, blinding and allocation concealment unclear</p>	<p>N= 54</p>	<p><b>Inclusion criteria:</b> patients with acute abdominal pain, clinical findings of abdominal tenderness in the left upper quadrant, nausea, or vomiting; a history of alcohol abuse or gallbladder disease; and laboratory findings of an increased amylase level +/- radiographic confirmation of pancreatic calcifications consistent with chronic pancreatitis.  <b>Exclusion criteria:</b> not reported  <b>Patient Characteristics:</b></p> <table border="1"> <thead> <tr> <th></th> <th>Early TPN</th> <th>Control</th> </tr> </thead> <tbody> <tr> <td>Age (yr)</td> <td>39.8± 2</td> <td>39.6± 3</td> </tr> <tr> <td>M/F</td> <td>19/10</td> <td>21/5</td> </tr> <tr> <td>Average Ranson's</td> <td>1.1± 0.20</td> <td>0.92± 0.17</td> </tr> </tbody> </table>		Early TPN	Control	Age (yr)	39.8± 2	39.6± 3	M/F	19/10	21/5	Average Ranson's	1.1± 0.20	0.92± 0.17	<p>TPN + conventional therapy (see comparison) started within 24 hrs of admission.  n=29</p>	<p>Conventional therapy (iv fluids, analgesics, antacids, nasogastric insertion)  n=26</p>	<p>At least 15 days</p>	<p>Death, exacerbation of symptoms, length of hospital stay, complications</p>	<p>Nutritional support service.</p>		
					Early TPN	Control																
				Age (yr)	39.8± 2	39.6± 3																
				M/F	19/10	21/5																
				Average Ranson's	1.1± 0.20	0.92± 0.17																

			criteria score							
			Cause (%)							
			Alcohol	86	76					
			Biliary	7	8					
			Mixed	3	12					
			Undetermined	3	4					

**Effect Size**

**Outcomes**

**1. Length of stay**

- TPN + conventional therapy (n=29): mean no. of days 16
- Conventional therapy (n=26): mean no. of days 10
- P<0.04

**3. NG vs. NJ**

<b>Petrov MS, Correia MITD, Windsor JA. Nasogastric tube feeding in predicted severe acute pancreatitis. A systematic review of the literature to determine safety and tolerance.</b>	SR 1+	N=4 studies N=92 patients	<b>Study characteristics (2 studies included in meta-analysis):</b> RCTs of nasogastric versus nasojejunal feeding in patients with severe acute pancreatitis.	Enteral nutrition via nasogastric feeding N=43	Enteral nutrition via nasojejunal feeding N=36	5-7 days	Mortality, diarrhoea, pain exacerbation, intolerance of feeding (length of stay, Infected pancreatic necrosis, Patients with MOF, surgery - but not in meta-analysis)	Not reported									
	8 parameter quality score- range from 0-16 (16 as highest quality)-assessed 1. Method of selection 2. Baseline comparability 3. Withdrawals 4. Allocation concealment 5. Method of allocation 6. blinding 7. protocol of intervention 8. co-interventions  Of the 2 studies included in the meta-	N=2 studies in meta-analysis N=79 patients							<table border="1"> <tr> <td></td> <td>EATOCK 2005</td> <td>KUMAR 2006</td> </tr> <tr> <td>APACHE II score</td> <td>10 (median range 7-18)</td> <td>10.5±3.8 (mean±SD)</td> </tr> <tr> <td>Feeding start</td> <td>&lt;72 h after onset</td> <td>48-72 h of admission</td> </tr> <tr> <td>Feeding formula</td> <td>Semi-elemental</td> <td>Semi-elemental</td> </tr> <tr> <td>Duration of nutrition (days)</td> <td>5</td> <td>7</td> </tr> </table>		EATOCK 2005	KUMAR 2006	APACHE II score	10 (median range 7-18)	10.5±3.8 (mean±SD)	Feeding start	<72 h after onset
	EATOCK 2005	KUMAR 2006															
APACHE II score	10 (median range 7-18)	10.5±3.8 (mean±SD)															
Feeding start	<72 h after onset	48-72 h of admission															
Feeding formula	Semi-elemental	Semi-elemental															
Duration of nutrition (days)	5	7															
			Characteristics of patients receiving NG feeding														

<b>Journal of the Pancreas. 2008; 9(4):440-448.</b>	analysis, 1 had a quality score of 14 and the other 13.		EATOCK 2005	KUMAR 2006						
		No. patients	27	16						
		Age (years)	63 (median range 47-74)	43.3±12.8 (mean±SD)						
		Male:female	14:13	14:2						
		<b>Aetiology</b>								
		Biliary	16	8						
		Alcohol	6	4						
Other	5	4								

**Effect Size**

**Outcomes**

**1. Mortality**

- Nasogastric feeding resulted in a non-significant reduction in the risk of death:
  - RR 0.77; 95% CI 0.37- 1.62; p=0.50
  - NG feeding: 10/43; NJ feeding 11/36

**Authors' Conclusion:**

*'The meta-analysis also demonstrated that there was no difference between nasogastric and nasojejunal tube feeding with respect to safety and tolerance in the two available RCTs.'*

*'An adequately powered randomized trail on nasogastric versus nasojejunal feeding is required to support this approach before early nasogastric tube feeding can be established as the standard of care.'*

**Limitations**

- EATOCK 2005: some data on certain essential clinical outcomes were not reported. Plus jejunal tube feeding in this trial was probably duodenal because jejunal placement would have been difficult with the type of tubes and placement techniques they were using- meaning that both trial arms would have been equally as pro-inflammatory, thus affecting the results.
- KUMAR 2006: there was considerable delay after symptom onset in the NG and NJ groups (7.8±6.5; 5.7±4.7 days) in commencing enteral feeding.
- Both trials were underpowered to detect any difference or to prove equivalence between the groups for any clinical outcome.

Reference	Study type/ Evidence level	Number of patients	Patient characteristics	Intervention	Comparison	Length of follow-up	Outcome measures	Source of funding
-----------	----------------------------	--------------------	-------------------------	--------------	------------	---------------------	------------------	-------------------



<p><b>Kumar A, Singh N, Prakash S et al. Early enteral nutrition in severe acute pancreatitis: a prospective randomized controlled trial comparing nasojejunal and nasogastric routes. <i>Journal of Clinical Gastroenterology</i>. 2006; 40(5):431-434.</b></p>	<p>RCT 1+</p> <p>Randomised, ITT, unable to blind, allocation concealment unclear.</p> <p>Underpowered</p>	<p>N=31</p>	<p><b>Inclusion criteria:</b> patients with severe acute pancreatitis. The severity was defined according to Atlanta criteria- presence of organ failure and acute physiology and chronic health evaluation score of <math>\geq 8</math> or CT severity score <math>\geq 7</math>.</p> <p><b>Exclusion criteria:</b> delay of &gt;4 weeks between the onset of symptoms and presentation to the hospital, if they were already taking oral feeding at presentation, if there was acute exacerbation of chronic pancreatitis, or if they were in shock at the time of randomisation.</p> <p><b>Patient characteristics:</b> No statistically significant difference in any baseline characteristics in the 2 groups</p> <table border="1" data-bbox="741 762 1240 1158"> <thead> <tr> <th></th> <th>NJ group</th> <th>NG group</th> <th>P value</th> </tr> </thead> <tbody> <tr> <td>Age (yrs)</td> <td>35.57±12.53</td> <td>43.25±12.76</td> <td>0.108</td> </tr> <tr> <td>M/F</td> <td>11/3</td> <td>14/2</td> <td>0.642</td> </tr> <tr> <td>Aetiology</td> <td></td> <td></td> <td></td> </tr> <tr> <td>Gallstones</td> <td>4</td> <td>7</td> <td></td> </tr> <tr> <td>Alcohol</td> <td>4</td> <td>4</td> <td>0.85</td> </tr> <tr> <td>Gallstones + alcohol</td> <td>1</td> <td>1</td> <td></td> </tr> <tr> <td>idiopathic</td> <td>5</td> <td>4</td> <td></td> </tr> <tr> <td>Mean APACHE II score</td> <td>9.64±4.99</td> <td>10.50±3.78</td> <td>0.597</td> </tr> </tbody> </table>		NJ group	NG group	P value	Age (yrs)	35.57±12.53	43.25±12.76	0.108	M/F	11/3	14/2	0.642	Aetiology				Gallstones	4	7		Alcohol	4	4	0.85	Gallstones + alcohol	1	1		idiopathic	5	4		Mean APACHE II score	9.64±4.99	10.50±3.78	0.597	<p>Nasojejunal (NJ) feeding</p> <p>Both groups started treatment 48-72 hrs after transfer to hospital and were continued on treatment for 7 days</p> <p>N=14</p>	<p>Nasogastric (NG) feeding</p> <p>See intervention for more details</p> <p>N=16</p>	<p>7 days (and then until discharge, death or surgery)</p>	<p>Recurrence of pain, tolerance of feeding, biochemical parameters, length of hospital stay, death, infection rate, surgery.</p>	<p>Not reported</p>
	NJ group	NG group	P value																																									
Age (yrs)	35.57±12.53	43.25±12.76	0.108																																									
M/F	11/3	14/2	0.642																																									
Aetiology																																												
Gallstones	4	7																																										
Alcohol	4	4	0.85																																									
Gallstones + alcohol	1	1																																										
idiopathic	5	4																																										
Mean APACHE II score	9.64±4.99	10.50±3.78	0.597																																									

## DRAFT FOR CONSULTATION

### Effect size

#### 1. length of stay (days)

- NJ gp:  $29.93 \pm 25.54$
- NG gp:  $24.06 \pm 14.35$
- $P=0.437$

#### 2. infection rate (includes positive blood culture, tracheal aspirate, pancreatic aspirate and bile culture)

- NJ gp: 6/14
- NG gp: 7/16
- $P=0.467$

#### 3. Surgery

- NJ gp: 2/14
- NG gp: 1/16

<p><b>Eatock FC, Chong P, Menezes N et al. A randomized study of early nasogastric versus nasojejunal feeding in severe acute pancreatitis. American Journal of Gastroenterology. 2005; 100(2):432-439.</b></p>	<p>RCT 1+  Randomised, ITT, unable to blind, allocation concealment unclear.  Underpowered</p>	<p>N=49</p>	<p><b>Inclusion criteria:</b> patients with both a clinical and biochemical presentation of acute pancreatitis (abdominal pain + serum amylase at least 3 times the upper limit of the reference range), and objective evidence of disease severity (Glasgow prognostic score 3 or more, or a APACHE II score 6 or more or a CRP level &gt;150 mg/L) <b>Exclusion criteria:</b> patients under 18 yrs and pregnant females. <b>Patient characteristics:</b></p> <table border="1" data-bbox="741 611 1240 1018"> <thead> <tr> <th></th> <th>NG group</th> <th>NJ group</th> <th>P value</th> </tr> </thead> <tbody> <tr> <td>Age median (IQR)</td> <td>63 (47-74)</td> <td>58 (48-64)</td> <td>0.47</td> </tr> <tr> <td>M/F</td> <td>14/13</td> <td>12/10</td> <td>-</td> </tr> <tr> <td>Feeding start-hrs from onset of pain (IQR)</td> <td>72 (24-72)</td> <td>72 (24-72)</td> <td>-</td> </tr> </tbody> </table> <p>Aetiology: Gallstones: 65.3% (16 in each group) Alcohol abuse: 24.5% Idiopathic:6.1%</p>		NG group	NJ group	P value	Age median (IQR)	63 (47-74)	58 (48-64)	0.47	M/F	14/13	12/10	-	Feeding start-hrs from onset of pain (IQR)	72 (24-72)	72 (24-72)	-	<p>Nasogastric feeding  N=27</p>	<p>Nasojejunal feeding  N=22</p>	<p>4 days</p>	<p>CRP, APACHE II score, pain score, analgesic requirement, need for conversion from EN to PN feeding, hospital and intensive care stay, mortality.</p>	<p>Not reported</p>
	NG group	NJ group	P value																					
Age median (IQR)	63 (47-74)	58 (48-64)	0.47																					
M/F	14/13	12/10	-																					
Feeding start-hrs from onset of pain (IQR)	72 (24-72)	72 (24-72)	-																					
<p><b>Effect Size</b> 1. Length of stay (days)</p> <ul style="list-style-type: none"> <li>• NG group: 16 (10-22)</li> <li>• NJ group: 15(10-42)</li> </ul>																								